# US 2021/0275519 A1 · Nasal drug products and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275519 A1
- Document ID: US20210275519A1
- Status: Published application
- Kind: A1
- Application number: 17/127,649
- Filed: 2020-12-18
- Published: 2021-09-09
- Earliest claimed: 2014-03-14
- Assignees: Opiant Pharmaceuticals, Inc.
- Applicants: Opiant Pharmaceuticals, Inc.
- Inventors: Roger CRYSTAL; Michael Brenner WEISS
- Web page: https://patentgrep.com/patent/US20210275519A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61M 11/001: {Particle size control}
- A61M 11/006: {operated by applying mechanical pressure to the liquid to be sprayed or atomised}
- A61M 15/08: Inhaling devices inserted into the nose
- A61M 31/00: Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

## Claims

### Claim 1

A pharmaceutical formulation for intranasal administration comprising, in an aqueous solution of not more than about 140 μL:
about 2 mg naloxone hydrochloride;
about 0.74 mg NaCl;
about 0.01 mg benzalkonium chloride;
about 0.2 mg disodium edetate; and
an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the aqueous solution has a volume of 100 μL.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, which yields, when intranasally administered to a patient, a mean naloxone plasma concentration of >0.2 ng/mL within 2.5 minutes, a mean naloxone plasma concentration of >1 ng/mL within 5 minutes, or a mean naloxone plasma concentration of >3 ng/mL within 10 minutes in said patient.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, which yields, when intranasally administered to a patient, a naloxone Tmax selected from the group consisting of less than 30 minutes, less than 25 minutes and less than 20 minutes.

### Claim at position 6

7-8. (canceled)

### Claim 9

A single-use, pre-primed device adapted for nasal delivery of a pharmaceutical composition to a patient by one actuation of said device into one nostril of said patient, having a single reservoir comprising a pharmaceutical composition which comprises per 100 μL of aqueous solution:
about 2 mg naloxone hydrochloride;
between about 0.2 mg and about 1.2 mg of an isotonicity agent;
between about 0.005 mg and about 0.015 mg of a preservative;
between about 0.1 mg and about 0.5 mg of a stabilizing agent; and
an amount of an acid sufficient to achieve a pH of 3.5-5.5.

### Claim 10 (depends on 9)

The device as recited in claim 9, wherein the device has at least one of the following features:
a. the isotonicity agent is NaCl, the preservative is benzalkonium chloride the stabilizing agent is disodium edetate, and the acid is hydrochloric acid;
b. the aqueous solution comprises per 100 μL: about 2 mg naloxone hydrochloride, about 0.74 mg NaCl, about 0.01 mg benzalkonium chloride, about 0.2 mg disodium edetate, and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5;
c. the device is actuatable with one hand;
d. the volume of said reservoir is not more than about 140 μL;
e. about 100 μL of said aqueous solution in said reservoir is delivered to said patient in one actuation;
f. the pharmaceutical composition which is an aqueous solution comprises about 2 mg naloxone hydrochloride;
g. the device is configured such that 90% confidence interval for dose delivered per actuation is about ±2%;
h. the device is configured such that 95% confidence interval for dose delivered per actuation is about ±2.5%;
i. the device is configured such that delivery time is less than about 25 seconds;
j. the device is configured such that delivery time is less than about 20 seconds.

### Claim at position 9

11-19. (canceled)

### Claim 20 (depends on 9)

A method of treatment of opioid overdose or a symptom thereof, comprising nasally administering to a patient in need thereof a dose of naloxone hydrochloride from the device of claim 9.

### Claim 21 (depends on 20)

The method of claim 20, wherein the method has at least one of the following features:
a. (i) the isotonicity agent is NaCl, (ii) the compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer is benzalkonium chloride, (iii) the stabilizing agent is disodium edetate, and (iv) the acid is hydrochloric acid;
b. the aqueous solution comprises about 2 mg naloxone hydrochloride, about 0.74 mg NaCl, about 0.01 mg benzalkonium chloride, about 0.2 mg disodium edetate, and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5;
c. the device is actuatable with one hand;
d. the volume of said reservoir is not more than about 140 μL;
e. wherein the plasma concentration versus time curve of said naloxone hydrochloride in said patient has a Tmax of between about 20 and about 30 minutes.

### Claim at position 12

22-24. (canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein when the volume of said reservoir is not more than about 140 μL, about 100 μL of said aqueous solution in said reservoir is delivered to said patient in one actuation.

### Claim 26 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition which is an aqueous solution comprises 2 mg naloxone hydrochloride.

### Claim 27 (depends on 26)

The method of claim 26, wherein the method has at least one of the following features:
a. 90% confidence interval for dose delivered per actuation is about ±2%;
b. 95% confidence interval for dose delivered per actuation is about ±2.5%;
c. delivery time is less than about 25 seconds;
d. delivery time is less than about 20 seconds.

### Claim at position 16

28-30. (canceled)

### Claim 31 (depends on 21)

The method of claim 21, wherein when the method has feature b, upon nasal delivery of said pharmaceutical composition to said patient, less than about 20% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally, less than about 10% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally, or less than about 5% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally.

### Claim at position 18

32-34. (canceled)

### Claim 35 (depends on 20)

The method of claim 20, wherein said patient is an opioid overdose patient or a suspected opioid overdose patient.

### Claim 36 (depends on 35)

The method of claim 35, wherein the patient exhibits one or more symptoms chosen from: respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing; erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting.

### Claim 37 (depends on 36)

The method of claim 36, wherein the patient exhibits respiratory depression and wherein the method has at least one of the following features:
a. said respiratory depression is caused by the illicit use of opioids, or by an accidental misuse of opioids during medical opioid therapy;
b. said patient is free from respiratory depression for at least about 1 hour following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
c. patient is free from respiratory depression for at least about 2 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
d. said patient is free from respiratory depression for at least about 4 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
e. said patient is free from respiratory depression for at least about 6 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
f. said patient is in a lying, supine, or recovery position.

### Claim at position 22

38-43. (canceled)

### Claim 44 (depends on 9)

A method of complete or partial reversal of narcotic depression or respiratory depression induced by opioids in a patient, comprising nasally administering to a patient in need thereof a dose of naloxone hydrochloride from the device of claim 9.

### Claim 45 (depends on 44)

The method of claim 44, wherein the method has at least one of the following features:
a. the isotonicity agent is NaCl, the compound which is at least one of a preservative, a cationic surfactant, and a permeation enhancer is benzalkonium chloride, the stabilizing agent is disodium edetate, and the acid is hydrochloric acid;
b. the aqueous solution comprises about 2 mg naloxone hydrochloride, about 0.74 mg NaCl, about 0.01 mg benzalkonium chloride, about 0.2 mg disodium edetate, and an amount of hydrochloric acid sufficient to achieve a pH of 3.5-5.5;
c. the method is actuatable with one hand;
d. volume of said reservoir is not more than about 140 μL;
e. plasma concentration versus time curve of said naloxone hydrochloride in said patient has a Tmax of between about 20 and about 30 minutes;
f. said patient is an opioid overdose patient or a suspected opioid overdose patient.

### Claim at position 25

46-48. (canceled)

### Claim 49 (depends on 45)

The method of claim 45, wherein when the volume of said reservoir is not more than about 140 μL, about 100 μL of said aqueous solution in said reservoir is delivered to said patient in one actuation.

### Claim 50 (depends on 49)

The method of claim 49, wherein the method has at least one of the following features:
a. the pharmaceutical composition which is an aqueous solution comprises 2 mg naloxone hydrochloride;
b. 90% confidence interval for dose delivered per actuation is about ±2%;
c. 95% confidence interval for dose delivered per actuation is about ±2.5%;
d. delivery time is less than about 25 seconds;
e. delivery time is less than about 20 seconds;
f. the pharmaceutical composition which is an aqueous solution comprises 2 mg naloxone hydrochloride and wherein the delivery time is less than about 25 seconds;
g. the pharmaceutical composition which is an aqueous solution comprises 2 mg naloxone hydrochloride and wherein the delivery time is less than about 20 seconds.

### Claim at position 28

51-54. (canceled)

### Claim 55 (depends on 45)

The method of claim 45, wherein when the method has feature b, upon nasal delivery of said pharmaceutical composition to said patient, less than about 20% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally, less than about 10% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally, or less than about 5% of said pharmaceutical composition leaves the nasal cavity via drainage into the nasopharynx or externally.

### Claim at position 30

56-59. (canceled)

### Claim 60 (depends on 45)

The method of claim 45, wherein when said patient is an opioid overdose patient or a suspected opioid overdose patient, the patient exhibits one or more symptoms chosen from: respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing; erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting.

### Claim 61 (depends on 60)

The method of claim 60, wherein the patient exhibits respiratory depression and wherein the method has at least one of the following features:
a. said respiratory depression is caused by the illicit use of opioids, or by an accidental misuse of opioids during medical opioid therapy;
b. said patient is free from respiratory depression for at least about 1 hour following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
c. said patient is free from respiratory depression for at least about 2 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
d. said patient is free from respiratory depression for at least about 4 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
e. said patient is free from respiratory depression for at least about 6 hours following treatment comprising delivery of said therapeutically effective amount of said opioid antagonist;
f. said patient is in a lying, supine, or recovery position.

### Claim at position 33

62-67. (canceled)